116 related articles for article (PubMed ID: 28596831)
1. Ofatumumab-associated acute pneumonitis: Not new but still the first case.
Bonanni A; Bertelli E; Panicucci C; D'Alessandro M; Moscatelli A; Lampugnani E; Sacco O; Magnano GM; Ravani P; Ghiggeri GM
Pharmacol Res Perspect; 2017 Feb; 5(1):e00267. PubMed ID: 28596831
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
[TBL] [Abstract][Full Text] [Related]
3. A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome.
Spatafora M; Bellini T; Giordano C; Ghiggeri GM
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26661285
[TBL] [Abstract][Full Text] [Related]
4. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
Basu B; Angeletti A; Islam B; Ghiggeri GM
Front Immunol; 2022; 13():805697. PubMed ID: 35222385
[TBL] [Abstract][Full Text] [Related]
5. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
6. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome.
Bonanni A; Rossi R; Murtas C; Ghiggeri GM
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26376698
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab for the treatment of childhood nephrotic syndrome.
Wang CS; Liverman RS; Garro R; George RP; Glumova A; Karp A; Jernigan S; Warshaw B
Pediatr Nephrol; 2017 May; 32(5):835-841. PubMed ID: 28213687
[TBL] [Abstract][Full Text] [Related]
8. First case report of using Ofatumumab in kidney transplantation AB0 incompatible.
Mancianti N; Monaci G; Rollo F; Buracchi P; Guarnieri A; Di Luca M; Martello M; Garosi G
G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207227
[TBL] [Abstract][Full Text] [Related]
9. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Bitzan M; Anselmo M; Carpineta L
Pediatr Pulmonol; 2009 Sep; 44(9):922-34. PubMed ID: 19681063
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
11. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Herter S; Herting F; Mundigl O; Waldhauer I; Weinzierl T; Fauti T; Muth G; Ziegler-Landesberger D; Van Puijenbroek E; Lang S; Duong MN; Reslan L; Gerdes CA; Friess T; Baer U; Burtscher H; Weidner M; Dumontet C; Umana P; Niederfellner G; Bacac M; Klein C
Mol Cancer Ther; 2013 Oct; 12(10):2031-42. PubMed ID: 23873847
[TBL] [Abstract][Full Text] [Related]
12. IgA Deficiency and Nephrotic Syndrome in Children.
Di Genova L; Ceppi S; Stefanelli M; Esposito S
Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30096909
[No Abstract] [Full Text] [Related]
13. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab.
Masoud S; McAdoo SP; Bedi R; Cairns TD; Lightstone L
Rheumatology (Oxford); 2018 Jul; 57(7):1156-1161. PubMed ID: 29562252
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
15. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
16. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome.
Bernard J; Bruel A; Allain-Launay E; Dantal J; Roussey G
Pediatr Transplant; 2018 Jun; 22(4):e13175. PubMed ID: 29569812
[TBL] [Abstract][Full Text] [Related]
17. Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.
Grenda R; Jarmużek W; Rubik J; Piątosa B; Prokurat S
Eur J Pediatr; 2016 Sep; 175(9):1133-1137. PubMed ID: 27364906
[TBL] [Abstract][Full Text] [Related]
18. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
20. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
